Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest

Saved in:
Bibliographic Details
Published in:Skin (Milwood, N.Y.) N.Y.), 2022-11, Vol.6 (6), p.s79
Main Authors: Reich, Kristian, Simpson, Eric L, Langley, Richard, Warren, Richard B, Costanzo, Antonio, Saeki, Hidehisa, Almgren, Peter, Gjerum, Le, Carlsson, Anna, Gooderham, Melinda, Pinter, Andreas, De Bruin-Weller, Marjolein, Blauvelt, Andrew
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2574-1624
2574-1624
DOI:10.25251/skin.6.supp.79